Vaš brskalnik ne omogoča JavaScript!
JavaScript je nujen za pravilno delovanje teh spletnih strani. Omogočite JavaScript ali pa uporabite sodobnejši brskalnik.
Nacionalni portal odprte znanosti
Odprta znanost
DiKUL
slv
|
eng
Iskanje
Brskanje
Novo v RUL
Kaj je RUL
V številkah
Pomoč
Prijava
Combinatory effect of nitroxoline and gentamicin in the control of uropathogenic enterococci infections
ID
Repac Antić, Davorka
(
Avtor
),
ID
Kovač, Bruno
(
Avtor
),
ID
Kolenc, Marko
(
Avtor
),
ID
Brčić Karačonji, Irena
(
Avtor
),
ID
Gobin, Ivana
(
Avtor
),
ID
Petković Didović, Mirna
(
Avtor
)
PDF - Predstavitvena datoteka,
prenos
(2,07 MB)
MD5: AEA6565F8B1A90B138B44C90761A05D0
URL - Izvorni URL, za dostop obiščite
https://www.mdpi.com/2079-6382/13/9/829
Galerija slik
Izvleček
Enterococcus faecalis, responsible for a majority of human and nosocomial enterococcal infections, is intrinsically resistant to aminoglycoside antibiotics (such as gentamicin, GEN), which must be used in a combined therapy to be effective. Nitroxoline (NTX) is an old antibiotic, underused for decades, but rediscovered now in an era of growing antibiotic resistance. In this in vitro study, the types of interactions between NTX and GEN on 29 E. faecalis strains were analyzed with an aim to find synergistic antimicrobial and antiadhesion combinations. Transmission electron microscopy (TEM) and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) were used to analyze changes in cell morphology and bacterial proteome after monotreatments and combined treatments. The results showed the synergistic effect for six combinations on eight strains, including the ATCC29212, and an additive effect for most strains. Combinations causing a complete inhibition of adhesion were established. Cell membrane integrity was affected by NTX, while combined NTX/GEN treatment caused dramatic changes in cell morphology. Upregulation of the expression of many proteins was established, with some emerging only after combined treatment. The results strongly imply that NTX has the potential for use in combined therapy with GEN against enterococci and it could further provide a substantial contribution to an ongoing fight against antimicrobial resistance and nosocomial infections.
Jezik:
Angleški jezik
Ključne besede:
synergism
,
enterococci
,
E. faecalis
,
antiadhesion
,
proteome
,
antimicrobial resistance
Vrsta gradiva:
Članek v reviji
Tipologija:
1.01 - Izvirni znanstveni članek
Organizacija:
FGG - Fakulteta za gradbeništvo in geodezijo
Status publikacije:
Objavljeno
Različica publikacije:
Objavljena publikacija
Leto izida:
2024
Št. strani:
19 str.
Številčenje:
Vol. 13, iss. 9, art. 829
PID:
20.500.12556/RUL-161268-ea564a48-f2f1-6ade-3ffd-9c7a92770f9e
UDK:
615
ISSN pri članku:
2079-6382
DOI:
10.3390/antibiotics13090829
COBISS.SI-ID:
206514691
Datum objave v RUL:
09.09.2024
Število ogledov:
28
Število prenosov:
25
Metapodatki:
Citiraj gradivo
Navadno besedilo
BibTeX
EndNote XML
EndNote/Refer
RIS
ABNT
ACM Ref
AMA
APA
Chicago 17th Author-Date
Harvard
IEEE
ISO 690
MLA
Vancouver
:
Kopiraj citat
Objavi na:
Gradivo je del revije
Naslov:
Antibiotics
Skrajšan naslov:
Antibiotics
Založnik:
MDPI AG
ISSN:
2079-6382
COBISS.SI-ID:
522975769
Licence
Licenca:
CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:
http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:
To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Sekundarni jezik
Jezik:
Slovenski jezik
Ključne besede:
sinergizem
,
enterokoki
,
E. faecalis
,
antiadhezija
,
proteom
,
protimikrobna odpornost
Projekti
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
University of Rijeka grants
Številka projekta:
uniri-iskusni-prirod-23-92
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
University of Rijeka grants
Številka projekta:
uniri-iskusni-biomed-23-110
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
European Regional Development Fund
Številka projekta:
KK.01.1.1.02.0007 (Rec-IMI)
Financer:
Drugi - Drug financer ali več financerjev
Program financ.:
European Union—Next Generation
Številka projekta:
EU 533-03-23-0006 (BioMolTox)
Podobna dela
Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:
Nazaj